IL-17 Blockade: Is Dual Inhibition Better Than Single for Psoriasis?

Interleukin-17 (IL-17) plays a central role in the pathogenesis of chronic inflammatory conditions like psoriasis and psoriatic arthritis. For a considerable period, the prevailing understanding suggested that IL-17A was the primary cytokine driving these diseases, leading to the development of selective IL-17A inhibitors. But preclinical and early clinical investigations began to hint that dual blockade of both IL-17A and IL-17F might offer a more comprehensive therapeutic approach, potentially leading to superior clinical outcomes. This hypothesis has now been tested in a series of phase II and III trials, comparing the dual inhibitor bimekizumab against established therapies such as secukinumab and adalimumab.¹

Bimekizumab is a humanized monoclonal antibody designed to specifically inhibit both IL-17A and IL-17F. This dual mechanism distinguishes it from earlier IL-17 inhibitors, such as secukinumab, which selectively target IL-17A. The rationale for dual inhibition stems from evidence that IL-17F, while structurally similar to IL-17A, also contributes significantly to inflammatory processes in psoriasis and psoriatic arthritis. By blocking both isoforms, bimekizumab aims to achieve a more complete suppression of the IL-17 pathway. The trials evaluating bimekizumab enrolled patients with moderate-to-severe plaque psoriasis and psoriatic arthritis, populations often requiring advanced systemic treatments due to the debilitating nature of their disease.¹

The Dual Blockade Advantage

Bimekizumab consistently demonstrated superior efficacy across multiple endpoints in patients with moderate-to-severe plaque psoriasis. In head-to-head trials, bimekizumab achieved a Psoriasis Area and Severity Index (PASI) 90 response in 68-85% of patients, a measure indicating a 90% improvement from baseline. This performance often surpassed that of secukinumab, a well-established IL-17A inhibitor, and adalimumab, a TNF-alpha blocker. For instance, one study reported bimekizumab achieving PASI 90 in 75% of patients compared to 55% for secukinumab at week 16 (P<.001).¹

The higher response rates with bimekizumab extended to more stringent endpoints, including PASI 100 (complete skin clearance). Patients receiving bimekizumab achieved PASI 100 in 50-60% of cases, a significant improvement over comparators. This level of skin clearance is a critical goal for many patients, impacting quality of life profoundly. The rapid onset of action was also a notable feature, with many patients showing significant improvement as early as week 4.¹

In psoriatic arthritis, bimekizumab also showed robust efficacy. Patients experienced significant improvements in American College of Rheumatology (ACR) response criteria, a composite measure of disease activity. ACR20 response rates with bimekizumab were consistently higher than placebo and comparable to, or exceeding, adalimumab in some studies. This suggests that the dual IL-17A/F blockade effectively addresses both the cutaneous and articular manifestations of psoriatic disease.¹

Safety and Tolerability Profile

The safety profile of bimekizumab generally aligns with that of other IL-17 inhibitors. The most commonly reported adverse events included nasopharyngitis, upper respiratory tract infections, and oral candidiasis. Oral candidiasis, while typically mild to moderate, occurred at a higher rate with bimekizumab compared to selective IL-17A inhibitors. This is likely due to the broader blockade of IL-17, which plays a role in mucosal immunity. But these infections were generally manageable with standard antifungal treatments and rarely led to treatment discontinuation.¹

Serious adverse events were infrequent and comparable across bimekizumab and comparator groups. There were no unexpected safety signals or increases in major adverse cardiovascular events (MACE) or malignancy. The long-term safety data, while still accumulating, appears consistent with the class. Clinicians should, however, remain vigilant for opportunistic infections, particularly mucocutaneous candidiasis, and counsel patients accordingly.¹

Comparing Mechanisms and Clinical Impact

The observed efficacy advantage of bimekizumab over secukinumab and adalimumab provides strong support for the hypothesis that IL-17F contributes significantly to the inflammatory cascade in psoriasis and psoriatic arthritis. While IL-17A has long been recognized as a key driver, the additional inhibition of IL-17F appears to offer a more complete suppression of the pathway, leading to enhanced clinical responses. This mechanistic distinction is important for understanding the therapeutic positioning of bimekizumab within the evolving market of biologic treatments.¹

Adalimumab, as a TNF-alpha inhibitor, operates through a different pathway. While effective, its efficacy ceiling in terms of complete skin clearance (PASI 100) is generally lower than that of IL-17 inhibitors. The direct comparison trials confirm that IL-17 blockade, particularly dual blockade, can achieve deeper and more rapid responses in a significant proportion of psoriasis patients. This offers an important alternative for patients who may not respond adequately to TNF-alpha inhibitors or who experience side effects. For those looking for a comprehensive guide to managing such conditions, the Oxford Handbook of Rheumatology (5th ed) provides an excellent reference.

The systematic review and network meta-analysis by Husein-ElAhmed and Husein-ElAhmed, though focused on hidradenitis suppurativa, reinforces the importance of understanding comparative efficacy across biologics.² While the direct application to psoriasis and PsA is limited by the different disease context, the methodology highlights the need for robust comparisons to inform therapeutic positioning. The review highlights that IL-17 is critical in various inflammatory skin conditions, and the specific isoforms targeted can influence outcomes.²

Where it Falls Short

While the data for bimekizumab are compelling, some caveats remain. The follow-up duration in many of the key trials, while sufficient for regulatory approval, does not fully capture very long-term efficacy and safety beyond one or two years. Real-world data will be essential to confirm these findings in broader, less selected patient populations. While bimekizumab demonstrated superiority over secukinumab and adalimumab, direct comparisons against other newer biologics, such as IL-23 inhibitors, are still emerging. This makes definitive positioning within the entire biologic armamentarium somewhat complex. The trials were also primarily focused on moderate-to-severe disease, and its role in milder forms or as a first-line agent in all patients requires further investigation. For a deeper dive into how different treatment strategies are evolving, our coverage on RA treatment optimisation offers relevant insights into applying progress in chronic inflammatory diseases.

The increased incidence of oral candidiasis, while manageable, is a practical consideration for clinicians and patients. It necessitates patient education and potentially prophylactic measures in some cases. The cost-effectiveness of bimekizumab compared to other biologics will also be a critical factor in its uptake and reimbursement decisions across European healthcare systems. These economic considerations often influence real-world prescribing patterns as much as, if not more than, raw efficacy data. Understanding the full spectrum of options and their comparative benefits is key, as discussed in our piece on navigating treatment choices in RA care.

The specific patient characteristics that predict a better response to dual IL-17A/F blockade versus selective IL-17A or other mechanisms are not yet fully elucidated. Biomarkers that could guide treatment selection would significantly enhance precision medicine in psoriasis and psoriatic arthritis. Without such markers, treatment decisions often rely on trial-and-error, which can delay optimal patient outcomes. The ongoing research into the oral-systemic link in RA and periodontitis illustrates the complexity of identifying such predictive factors in chronic inflammatory conditions.

The current evidence strongly supports bimekizumab as a highly effective option for patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. Its dual mechanism of action appears to translate into superior clinical outcomes compared to single IL-17A blockade and TNF-alpha inhibition. The main challenge now lies in integrating this potent new therapy into existing treatment algorithms, considering its distinct safety profile and the need for more long-term comparative data against the full range of available biologics.